Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
CC transcript
Acq. announced
Director departure
NOVAVAX INC (NVAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S."
08/22/2023 4 Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC
Txns: Paid exercise price by delivering 317 shares @ $7.14, valued at $2.3k
Exercised 655 restricted stock units @ $0
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights"
08/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "At Market Issuance Sales Agreement by and among Novavax, Inc., Jefferies LLC and B. Riley Securities, Inc.",
"Opinion of Ropes & Gray LLP"
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "SECURITIES SUBSCRIPTION AGREEMENT This SECURITIES SUBSCRIPTION AGREEMENT is made and entered into this 8th day of August, 2023 by and among Novavax, Inc., a Delaware corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 , and SK bioscience Co., Ltd., a company incorporated in the Republic of Korea having a place of business at 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494, Republic of Korea . The Company and SK shall each be hereinafter referred to as a “Party” and collectively as the “Parties”. WHEREAS, the Company and SK are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended ; and WHEREAS, the Company desires to issue to SK, shares of ..."
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/11/2023 8-K Quarterly results
07/07/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/07/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
06/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/10/2023 SC 13G/A STATE STREET CORP reports a 12.1% stake in AMENDED FILING NOVAVAX INC
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2023 Financial Results and Operational Highlights",
"Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccines Demonstrate Robust Immune Responses"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/04/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BY-LAWS"
03/22/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 4 Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC
Txns: Exercised 4,609 shares @ $6.52, valued at $30.1k
Paid exercise price by delivering 2,471 shares @ $6.52, valued at $16.1k
Exercised 4,609 restricted stock units @ $0
03/14/2023 4 Kelly James Patrick (EVP, CFO and Treasurer) has filed a Form 4 on NOVAVAX INC
Txns: Exercised 4,609 shares @ $6.52, valued at $30.1k
Paid exercise price by delivering 2,471 shares @ $6.52, valued at $16.1k
Exercised 4,609 restricted stock units @ $0
03/14/2023 4 Herrmann John A III (EVP, Chief Legal Officer) has filed a Form 4 on NOVAVAX INC
Txns: Exercised 4,609 shares @ $6.52, valued at $30.1k
Paid exercise price by delivering 1,780 shares @ $6.52, valued at $11.6k
Exercised 4,609 restricted stock units @ $0
03/14/2023 4 Glenn Gregory M (President, R&D) has filed a Form 4 on NOVAVAX INC
Txns: Bought 3,000 shares @ $7.4845, valued at $22.5k
Bought 2,000 shares @ $7.044, valued at $14.1k
Bought 1,000 shares @ $6.5, valued at $6.5k
Exercised 6,298 shares @ $6.52, valued at $41.1k
Paid exercise price by delivering 2,432 shares @ $6.52, valued at $15.9k
Exercised 6,298 restricted stock units @ $0
03/14/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 4 Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC
Txns: Granted 100,100 options to buy @ $6.97, valued at $697.7k
Granted 86,670 restricted stock units @ $0
03/09/2023 4 Kelly James Patrick (EVP, CFO and Treasurer) has filed a Form 4 on NOVAVAX INC
Txns: Granted 42,350 options to buy @ $6.97, valued at $295.2k
Granted 36,670 restricted stock units @ $0
03/09/2023 4 Herrmann John A III (EVP, Chief Legal Officer) has filed a Form 4 on NOVAVAX INC
Txns: Granted 44,280 options to buy @ $6.97, valued at $308.6k
Granted 38,330 restricted stock units @ $0
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy